🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Lactose Placebo

    United Therapeutics Europe Ltd

    Elbow Fracture

    phase 3 small molecule completed

    1 trial

  2. Lapaquistat acetate and lipid-lowering therapy

    Takeda

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  3. Lapaquistat acetate and stable statin therapy

    Takeda

    Hypercholesterolemia

    phase 3 small molecule terminated

    2 trials

  4. Lenvatinib

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 3 small molecule terminated

    1 trial

  5. Letrozole

    The First People's Hospital of Lianyungang

    Polycystic Ovary Syndrome

    phase 3 small molecule completed

    1 trial

  6. Levetiracetam NORMON 250 mg comprimidos recubiertos con película EFG, PLACEBO LEVETIRACETAM 250 mg, Levetiracetam NORMON 500 mg comprimidos recubiertos con película EFG, PLACEBO LEVETIRACETAM 500 mg

    The George Institute

    Down syndrome, Alzheimer's Disease

    phase 3 small molecule active

    1 trial

  7. Levosimendan

    TENAX THERAPEUTICS, INC.

    Coronary Artery Bypass Grafting

    phase 3 small molecule completed

    1 trial

  8. Levosimendan, The levosimendan placebo drug product is an immediate-release dosage form for oral administration.

    TENAX THERAPEUTICS, INC.

    Pulmonary Hypertension (PH) with Heart Failure with preserved left ventricular ejection fraction (PH-HFpEF)

    phase 3 small molecule active

    1 trial

  9. Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion

    Orchard Therapeutics (Netherlands) B.V.

    Metachromatic Leukodystrophy (MLD) is an autosomal recessive disorder caused by mutations

    phase 3 small molecule active

    1 trial

  10. Libmeldy 2-10 x 10^6 cells/mL dispersion for infusion

    Orchard Therapeutics (Netherlands) B.V.

    Metachromatic Leukodystrophy (MLD)

    phase 3 small molecule active

    1 trial

  11. Lifileucel plus Pembrolizumab

    Iovance Biotherapeutics B.V.

    Metastatic Melanoma

    phase 3 mab active

    1 trial

  12. Lokelma 5 g powder for oral suspension, Lokelma 10 g powder for oral suspension

    The George Institute

    Hyperkalemia in patients with chronic kidney disease

    phase 3 small molecule active

    1 trial

  13. Loncastuximab Tesirine

    ADC Therapeutics SA

    Relapsed Diffuse Large B-Cell Lymphoma

    phase 3 small molecule active

    1 trial

  14. Lonsurf 15 mg/6.14 mg film-coated tablets, FRUZAQLA 1 mg hard capsules, Lonsurf 20 mg/8.19 mg film-coated tablets, FRUZAQLA 5 mg hard capsules

    CERO THERAPEUTICS HOLDINGS, INC.

    metastatic oeso-gastric adenocarcinoma

    phase 3 small molecule active

    1 trial

  15. Lorundrostat Placebo Tablets, Lorundrostat, Synacthen 0,25 mg/ml Injektionslösung, Lorundrostat

    Mineralys Therapeutics

    Uncontrolled and Resistant Hypertension

    phase 3 small molecule active

    1 trial

  16. Lorundrostat, Lorundrostat, Synacthen 0,25 mg/ml Injektionslösung, Lorundrostat Placebo tablet, Lorundrostat

    Mineralys Therapeutics

    Hypertension

    phase 3 small molecule active

    1 trial

  17. Losmapimod

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy (FSHD)

    phase 3 small molecule terminated

    2 trials

  18. Losmapimod oral tablet

    Fulcrum Therapeutics

    COVID-19

    phase 3 small molecule terminated

    1 trial

  19. Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)

    United Therapeutics Europe Ltd

    TBI Depression

    phase 3 other completed

    1 trial

  20. Lucinactant

    WINDTREE THERAPEUTICS INC /DE/

    Meconium Aspiration

    phase 3 small molecule terminated

    1 trial

  21. Lumacaftor Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

    phase 3 small molecule completed

    1 trial

  22. Lumacaftor Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    phase 3 small molecule completed

    1 trial

  23. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria

    phase 3 small molecule completed

    1 trial

  24. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria Type 1

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources